Su et al. (2018) suggested that lncRNA H19 knockout protected mice from pulmonary artery remodeling and Pulmonary arterial hypertension (PAH) following monocrotaline (MCT) treatment (Su et al., 2018). Basing on our in-vitro finding, we also believed that targeting might be helpful in treating PAH. Anyhow, this needs to be confirmed in in-vivo experiments. Here, H19 is linked to pulmonary arterial hypertension.